Aurobindo Pharma Ltd (IN:AUROPHARMA)
:AUROPHARMA
Want to see IN:AUROPHARMA full AI Analyst Report?
AUROPHARMA Stock Chart & Stats
₹1207.35
-₹25.45(-1.99%)
At close: 4:00 PM EST
₹1207.35
-₹25.45(-1.99%)
Day’s Range― - ―
52-Week Range₹1,017.00 - ₹1,459.75
Previous CloseN/A
Volume696.31K
Average Volume (3M)40.80K
Market Cap
₹807.05B
Enterprise Value₹793.79B
Total Cash (Recent Filing)₹88.92B
Total Debt (Recent Filing)₹77.94B
Price to Earnings (P/E)18.9
Beta0.76
Next Earnings
Jun 01, 2026EPS Estimate
16.33Next Dividend Ex-DateN/A
Dividend Yield0.33%
Share Statistics
EPS (TTM)58.93
Shares Outstanding580,801,640
10 Day Avg. Volume31,329
30 Day Avg. Volume40,801
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)2.02
Price to Sales (P/S)2.08
P/FCF Ratio33.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,385.00Price Target Upside14.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)75.5
Revenue Forecast (FY)₹380.13B
Bulls Say, Bears Say
Bulls Say
Revenue & Margin ImprovementAurobindo's topline increase and improved gross (58.9%) and net (11%) margins indicate durable sales momentum and a healthier product mix. Sustained margin expansion across geographies supports long-term cash generation and reinvestment capacity for regulatory approvals and capacity.
Conservative Balance SheetA low debt-to-equity ratio and a strong equity base give the company flexibility to fund capex, comply with regulatory requirements, and pursue M&A without stressing liquidity. Conservative leverage improves resilience to pricing cycles in generics and APIs.
Free Cash Flow RecoveryThe swing to positive free cash flow reflects improved cash conversion and operational cash generation. Durable FCF supports debt reduction, capacity investments, and working-capital needs—key for a capital-intensive generics and API manufacturer over multiple quarters.
Bears Say
EBITDA Margin PressureA decline in EBITDA margin signals rising operating pressure. In a generics business where manufacturing efficiency and pricing drive profits, persistent margin erosion can reduce cash available for growth and returns unless offset by higher-value products or cost restructuring.
Modest ROEROE of 10.7% is satisfactory but modest for capital deployed in pharmaceuticals; sustained mid-to-high single-digit ROE may limit investor confidence. Improving capital allocation or launching higher-margin products is needed to materially lift long-term shareholder returns.
Moderate Revenue GrowthSingle-digit revenue growth around 7.3% is moderate for a company operating in regulated markets. Slower top-line expansion constrains scale benefits and margin leverage, making sustained profitability gains dependent on product mix shifts or operational efficiencies.
Aurobindo Pharma Ltd News
AUROPHARMA FAQ
What was Aurobindo Pharma Ltd’s price range in the past 12 months?
Aurobindo Pharma Ltd lowest stock price was ₹1017.00 and its highest was ₹1459.75 in the past 12 months.
What is Aurobindo Pharma Ltd’s market cap?
Aurobindo Pharma Ltd’s market cap is ₹807.05B.
When is Aurobindo Pharma Ltd’s upcoming earnings report date?
Aurobindo Pharma Ltd’s upcoming earnings report date is Jun 01, 2026 which is in 28 days.
How were Aurobindo Pharma Ltd’s earnings last quarter?
Aurobindo Pharma Ltd released its earnings results on Feb 09, 2026. The company reported ₹15.67 earnings per share for the quarter, missing the consensus estimate of ₹15.943 by -₹0.273.
Is Aurobindo Pharma Ltd overvalued?
According to Wall Street analysts Aurobindo Pharma Ltd’s price is currently Undervalued.
Does Aurobindo Pharma Ltd pay dividends?
Aurobindo Pharma Ltd pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.33%. See more information on Aurobindo Pharma Ltd dividends here
What is Aurobindo Pharma Ltd’s EPS estimate?
Aurobindo Pharma Ltd’s EPS estimate is 16.33.
How many shares outstanding does Aurobindo Pharma Ltd have?
Aurobindo Pharma Ltd has 580,801,640 shares outstanding.
What happened to Aurobindo Pharma Ltd’s price movement after its last earnings report?
Aurobindo Pharma Ltd reported an EPS of ₹15.67 in its last earnings report, missing expectations of ₹15.943. Following the earnings report the stock price went up 0.848%.
Which hedge fund is a major shareholder of Aurobindo Pharma Ltd?
Currently, no hedge funds are holding shares in IN:AUROPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aurobindo Pharma Ltd
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
AUROPHARMA Stock 12 Month Forecast
Average Price Target
₹1,385.00
▲(14.71% Upside)
Technical Analysis
Alkem Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
Laurus Labs Ltd.
―
Lupin Limited
―
Zydus Lifesciences Limited
―